The Neoadjuvant Administration of PD-1 Inhibitor plus Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous-Cell Carcinoma
Table 1
Clinical characteristics of locally advanced ESCC patients.
Characteristics
Locally advanced ESCC patients (N = 25)
Age (years), mean ± SD
59.7 ± 7.8
Gender, no. (%)
Female
7 (28.0)
Male
18 (72.0)
Tumor location, no. (%)
Upper
1 (4.0)
Middle
19 (76.0)
Lower
5 (20.0)
Histological type, no. (%)
ESCC
25 (100.0)
cT stage, no. (%)
cT2
2 (8.0)
cT3
23 (92.0)
cN stage, no. (%)
cN1
16 (64.0)
cN2
7 (28.0)
cN3
2 (8.0)
cM, no. (%)
cM0
25 (100.0)
cTNM, no. (%)
III
23 (92.0)
IVA
2 (8.0)
PD-1 regimen, no. (%)
Camrelizumab
12 (48.0)
Sintilimab
8 (32.0)
Others
5 (20.0)
Chemotherapy regimen, no. (%)
Paclitaxel + cisplatin
11 (44.0)
Paclitaxel + carboplatin
14 (56.0)
RT dose, no. (%)
40 Gy/20 F
13 (52.0)
41.4 Gy/23 F
12 (48.0)
PD-L1 CPS, no. (%)
0
0 (0.0)
1–4
13 (52.0)
5–9
8 (32.0)
≥10
4 (16.0)
ESCC, esophageal squamous-cell carcinoma; SD, standard deviation; cT, clinical tumor; cN, clinical node; cM, clinical metastasis; cTNM, clinical tumor-node-metastasis; PD-1, programmed cell death protein 1; RT, radiotherapy; 40 Gy/20 F, 40.0 Gy in 20 fractions; 41.4 Gy/23 F, 41.4 Gy in 23 fractions; PD-L1 CPS, programmed death ligand 1 combined positive score.